What is Provas (Paracetamol/Orphenadrine) and Tramadol?
Provas is a fixed-dose combination medication containing paracetamol (acetaminophen) 450 mg and orphenadrine 35 mg, used for musculoskeletal pain with muscle spasm, while tramadol is a centrally-acting weak opioid analgesic with dual mechanism (mu-opioid receptor agonist plus norepinephrine/serotonin reuptake inhibition) used for moderate to moderately severe pain. 1
Provas (Paracetamol/Orphenadrine Combination)
This combination provides both analgesic and muscle relaxant properties 1:
- Paracetamol component (450 mg): First-line analgesic recommended for musculoskeletal pain with favorable safety profile 2
- Orphenadrine component (35 mg): Muscle relaxant that addresses muscle spasm component of pain
- Clinical use: Widely available as generic for conditions involving both pain and muscle spasm 1
Key Considerations for Paracetamol Component:
- Maximum daily dose should not exceed 4 grams total from all sources 2
- Lower dosing recommended for patients with liver disease 2
- Can be continued when adding opioids if providing additional benefit 3
- Recommended as first-line agent for musculoskeletal pain due to fewer side effects than NSAIDs 2
Tramadol
Tramadol is an atypical centrally-acting analgesic with unique dual mechanism 4:
Mechanism of Action:
- Weak mu-opioid receptor agonist (approximately 1/10th potency of morphine) 5
- Inhibits norepinephrine and serotonin reuptake 6, 7, 5
- Active metabolite M1 has higher affinity for mu-receptors (up to 6 times more potent than parent drug) 4
Clinical Indications:
- Moderate to moderately severe pain 5, 4
- May be effective for osteoarthritis pain (37.5-400 mg daily in divided doses) 2
- Less effective than morphine for cancer pain 5
Dosing:
- Immediate-release: Start 50-100 mg every 4-6 hours, maximum 400 mg/day 5
- Extended-release: Maximum 300 mg/day 5
- Elderly (≥75 years): Lower doses required to reduce seizure risk 5
- Renal/hepatic impairment: Dose reduction necessary; not recommended if GFR <30 mL/min 6
Critical Safety Warnings:
Serotonin syndrome risk: Use with extreme caution or avoid entirely when combined with 6, 5:
- Tricyclic antidepressants
- SSRIs (selective serotonin reuptake inhibitors)
- SNRIs (serotonin-norepinephrine reuptake inhibitors)
- MAO inhibitors
Seizure risk: Increased with 5, 8, 5:
- High doses
- Predisposed patients
- Elderly patients
- Hepatic/renal dysfunction
Metabolism variability: Tramadol is a prodrug requiring CYP2D6 metabolism to active form 6, 3. CYP2D6 inhibitors reduce efficacy, while poor metabolizers may not achieve adequate analgesia 6.
Comparative Efficacy:
- Versus morphine: Less effective for cancer pain; produces more adverse effects (vomiting, dizziness, weakness) in some studies 5
- Versus NSAIDs/acetaminophen: May be suitable alternative when NSAIDs contraindicated 2
- Combination with paracetamol: More effective than tramadol alone for acute postoperative pain 9, 10
Common Adverse Effects:
- Nausea, dizziness, drowsiness, sweating, vomiting, dry mouth (1.6-6.1% incidence) 11
- Lower abuse potential compared to traditional opioids 11, 12
- No clinically significant respiratory or cardiovascular effects at recommended doses 11
Guideline Positioning:
Tramadol has limitations that make it less desirable than other opioids 3:
- Prodrug requiring metabolism
- Low threshold for neurotoxicity limiting dose titration
- Multiple drug interactions via CYP450 system
- Unknown whether dose-dependent overdose risk similar to pure mu-agonists 7
Clinical Bottom Line:
Provas combines paracetamol (first-line analgesic) with orphenadrine (muscle relaxant) for musculoskeletal conditions with spasm. Tramadol is a weak opioid with dual mechanism reserved for moderate pain when first-line agents fail, but carries significant drug interaction risks (especially serotonin syndrome) and metabolism variability that limit its utility compared to other opioids. When opioid therapy is needed, consider alternatives to tramadol unless specific contraindications exist to traditional opioids 3.